Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Interrupting a Molecular Signaling Pathway to Treat Prostate Cancer

By LabMedica International staff writers
Posted on 11 Jan 2017
Cancer researchers have traced a molecular pathway that is active in treatment resistant prostate cancer and have suggested therapeutic strategies to circumvent it.

Androgen deprivation therapy is the most effective treatment for advanced prostate cancer, but almost all cancer eventually becomes castration resistant, and the underlying mechanisms are largely unknown. More...
Investigators at The Scripps Research Institute (Juptier, FL, USA) recently identified one of these mechanisms.

They investigators reported in the December 29, 2016, online edition of the journal Molecular Cell that an intrinsic constitutively activated feedforward signaling circuit was formed during the emergence of castration-resistant prostate cancer (CRPC). This signaling pathway comprised the microRNA miR-196b-3p and the proteins IkappaBalpha (NF-kappaB inhibitor, alpha)/NF-kappaB (nuclear factor of kappa light polypeptide gene enhancer in B-cells), Meis2 (Homeobox protein Meis2), and PPP3CC (protein phosphatase 3 catalytic subunit gamma).

NF-kappaB inhibitor, alpha is one member of a family of cellular proteins that function to inhibit the NF-kappaB transcription factor. IkappaBalpha inhibits NF-kappaB by masking the nuclear localization signals of NF-kappaB proteins and keeping them sequestered in an inactive state in the cytoplasm. In addition, IkappaBalpha blocks the ability of NF-kappaB transcription factors to bind to DNA, which is required for NF-kappaB's proper functioning. Inactivation of the IkappaBalpha protein causes NF-kappaB to be chronically active in tumor cells and this activity contributes to the malignant state of these tumor cells.

The use of NF-kappaB inhibitors in treating cancer is complicated by severe side effects related to immunosuppression caused by indiscriminate inhibition of NF-kappaB in normal immune cells. However, the investigators suggested that targeting the other non-IkappaBalpha/NF-kappaB components in this signaling circuit would avoid the suppression of NF-kappaB in normal immune cells while keeping the potent anti-cancer efficacy.

"Disrupting this circuit by targeting any of its individual components blocks the expression of these transcription factors and significantly impairs therapy-resistant prostate cancer," said first author Dr. Ji-Hak Jeong, a research associate at The Scripps Research Institute.

Related Links:
The Scripps Research Institute



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.